Sodium-glucose cotransporter 2 inhibition: which patient with chronic kidney disease should be treated in the future?
SGLT2 inhibitors
chronic kidney disease
clinical outcomes
type 2 diabetes
Journal
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
ISSN: 1460-2385
Titre abrégé: Nephrol Dial Transplant
Pays: England
ID NLM: 8706402
Informations de publication
Date de publication:
01 01 2020
01 01 2020
Historique:
received:
20
09
2019
entrez:
1
2
2020
pubmed:
1
2
2020
medline:
5
9
2020
Statut:
ppublish
Résumé
The advent of sodium-glucose cotransporter 2 (SGLT2) inhibitors represents a major advance for people with type 2 diabetes (T2DM) and chronic kidney disease (CKD). The results of the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial have clearly demonstrated that canagliflozin prevents kidney failure and cardiovascular events. The results from three other large-scale randomized trials, collectively enrolling >30 000 participants, have provided further evidence that the effects of SGLT2 inhibition on major kidney outcomes in people with T2DM may be present across the class, although this will only be known for certain when Dapagliflozin and Renal Outcomes and Cardiovascular Mortality in Patients with CKD (DAPA-CKD) (NCT03036150) and The Study of Heart and Kidney Protection with Empagliflozin (EMPA-KIDNEY) (NCT03594110) are reported over coming years. Importantly, the benefits of SGLT2 inhibition have been achieved in addition to the current standard of care. This review summarizes evidence for SGLT2 inhibition in people with T2DM and CKD, evaluates key patient characteristics and concomitant drug use that may influence the use of these drugs in people with CKD, discusses current guideline recommendations and explores how these drugs may be used in people with CKD in the future, including in combination with other treatments.
Identifiants
pubmed: 32003833
pii: 5718401
doi: 10.1093/ndt/gfz252
pmc: PMC6993192
doi:
Substances chimiques
SLC5A2 protein, human
0
Sodium-Glucose Transporter 2
0
Sodium-Glucose Transporter 2 Inhibitors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
i48-i55Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA.
Références
Diabetes Care. 2019 Jan;42(Suppl 1):S90-S102
pubmed: 30559235
Lancet Diabetes Endocrinol. 2019 May;7(5):356-367
pubmed: 30833170
N Engl J Med. 2016 Jul 28;375(4):323-34
pubmed: 27299675
Lancet Diabetes Endocrinol. 2019 Nov;7(11):845-854
pubmed: 31495651
Clin Kidney J. 2018 Dec;11(6):749-761
pubmed: 30524708
Circulation. 2018 Jan 9;137(2):119-129
pubmed: 28904068
Diabetes Care. 2019 Oct;42(10):1886-1894
pubmed: 31221677
Lancet Diabetes Endocrinol. 2019 Oct;7(10):776-785
pubmed: 31422062
Circulation. 2018 Oct 9;138(15):1537-1550
pubmed: 29941478
Eur Heart J. 2016 May 14;37(19):1526-34
pubmed: 26819227
Lancet. 2019 Jan 5;393(10166):31-39
pubmed: 30424892
Endocr Pract. 2018 Jan;24(1):91-120
pubmed: 29368965
Adv Chronic Kidney Dis. 2015 Mar;22(2):88-95
pubmed: 25704344
N Engl J Med. 2019 Jan 24;380(4):347-357
pubmed: 30415602
Semin Nephrol. 2014 May;34(3):333-9
pubmed: 25016403
Diabetes Care. 2019 Jan;42(Suppl 1):S124-S138
pubmed: 30559237
Diabetes Care. 2004 Jan;27(1):195-200
pubmed: 14693989
Circulation. 2016 Dec 13;134(24):1915-1917
pubmed: 27956401
BMJ Glob Health. 2017 Jul 6;2(2):e000380
pubmed: 29225940
Diabetes Obes Metab. 2019 Feb;21(2):207-209
pubmed: 30178516
Clin J Am Soc Nephrol. 2018 Feb 7;13(2):318-320
pubmed: 28893920
N Engl J Med. 2017 Aug 17;377(7):644-657
pubmed: 28605608
Can J Diabetes. 2018 Apr;42 Suppl 1:S88-S103
pubmed: 29650116
Lancet Diabetes Endocrinol. 2019 Aug;7(8):606-617
pubmed: 31196815
Lancet Diabetes Endocrinol. 2015 Jul;3(7):514-25
pubmed: 26028594
Clin J Am Soc Nephrol. 2017 Dec 7;12(12):2032-2045
pubmed: 28522654
N Engl J Med. 2001 Sep 20;345(12):870-8
pubmed: 11565519
Lancet Diabetes Endocrinol. 2017 Aug;5(8):610-621
pubmed: 28666775
N Engl J Med. 2019 Jun 13;380(24):2295-2306
pubmed: 30990260
N Engl J Med. 2001 Sep 20;345(12):861-9
pubmed: 11565518
N Engl J Med. 2015 Nov 26;373(22):2117-28
pubmed: 26378978
J Am Coll Cardiol. 2018 Dec 18;72(24):3200-3223
pubmed: 30497881
Diabetologia. 2017 Sep;60(9):1620-1629
pubmed: 28770324
Circulation. 2016 Sep 6;134(10):752-72
pubmed: 27470878
Am J Kidney Dis. 2019 Nov;74(5):713-715
pubmed: 31255334
Circulation. 2019 Aug 27;140(9):739-750
pubmed: 31291786
Lancet Diabetes Endocrinol. 2018 May;6(5):370-381
pubmed: 29483060
J Am Soc Nephrol. 2019 Jul;30(7):1314-1321
pubmed: 31167823
Diabetes Care. 2018 Jan;41(1):14-31
pubmed: 29263194
J Am Soc Nephrol. 2019 Nov;30(11):2229-2242
pubmed: 31530577
Diabetes Care. 2011 May;34 Suppl 2:S320-4
pubmed: 21525476
Lancet Diabetes Endocrinol. 2018 Sep;6(9):691-704
pubmed: 29937267
Kidney Int. 2019 Aug;96(2):489-504
pubmed: 31142441
J Am Soc Nephrol. 2017 Jan;28(1):368-375
pubmed: 27539604
Diabetologia. 2018 Dec;61(12):2461-2498
pubmed: 30288571
Kidney Int. 2018 Sep;94(3):567-581
pubmed: 30078514
Kidney Int. 2011 Jul;80(1):93-104
pubmed: 21289597
N Engl J Med. 2019 Nov 21;381(21):1995-2008
pubmed: 31535829
Eur Heart J. 2013 Oct;34(39):3035-87
pubmed: 23996285
Diabetes Obes Metab. 2019 May;21(5):1237-1250
pubmed: 30697905
Nephrol Dial Transplant. 2019 Feb 1;34(2):208-230
pubmed: 30753708
Diabetes. 2006 Jun;55(6):1832-9
pubmed: 16731850
Kidney Int. 2019 Jun;95(6):1304-1317
pubmed: 31053387